Lu177‐PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Medical Imaging and Radiation Oncology"
DOI: 10.1111/1754-9485.13182
Abstract: Radioligand therapies, or ‘theranostics’, have an emerging role in patients with metastatic castration‐resistant prostate cancer (mCRPC). Lutetium‐177 (Lu), targeting prostate‐specific membrane antigen (PSMA), has demonstrated promising outcomes including reduced disease progression and improved overall survival.… read more here.
Keywords: lu177 psma; prostate cancer; therapy men; psma therapy ... See more keywords
Adjustable continence therapy for men (ProACTTM): systematic review and compendium of adverse events
Sign Up to like & getrecommendations! Published in 2025 at "Translational Andrology and Urology"
DOI: 10.21037/tau-24-587
Abstract: Background Adjustable continence therapy for men (ProACTTM) is an inflatable para-urethral balloon approved for consumer use in the United States by the Food and Drug Administration in 2015. Post-approval adverse events (AEs) have been catalogued… read more here.
Keywords: device; adjustable continence; therapy men; continence therapy ... See more keywords